Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Company Overview
Palisade Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies that protect the intestinal barrier, a critical factor in maintaining gastrointestinal health. The company focuses on a targeted approach within the IBD treatment space, addressing conditions such as ulcerative colitis and Crohn's disease. By honing in on the integrity of the intestinal barrier, Palisade Bio Inc aims to provide novel solutions for patients suffering from chronic inflammatory disorders.
Core Research and Development Focus
The focus on intestinal barrier protection marks a distinctive niche in a broader biopharma landscape. The company is engaged in clinical-stage research that explores therapeutic mechanisms designed to enhance the barrier function of the intestines, which plays a pivotal role in managing inflammatory bowel diseases. This strategic therapeutic target is underpinned by robust scientific inquiry and a commitment to addressing unmet medical needs in gastroenterology.
Business Model and Market Position
Operating at the clinical stage, Palisade Bio Inc generates value primarily through the advancement of its research pipeline, which is supported by research collaborations and licensing agreements. The company’s operational model is predicated on rigorous clinical research and methodical drug development processes rather than immediate commercial product sales. This developmental stage is characteristic of many companies in the biopharmaceutical sector, where the emphasis is on scientific innovation and proof-of-concept studies.
Industry Context and Competitive Landscape
Within the highly competitive landscape of the biopharma industry, Palisade Bio Inc distinguishes itself through its specialized approach. Instead of a broad-based product portfolio, the company concentrates its efforts on the enhancement of intestinal barrier function, which is recognized as a critical determinant in the progression of gastrointestinal disorders. This focused strategy allows it to navigate the complexities of clinical research while addressing a specific therapeutic need that differentiates it from competitors.
Research Pipeline and Therapeutic Strategy
The company is committed to an innovative research agenda that involves multiple therapeutic candidates aimed at modulating the intestinal barrier. The approach underscores a deep expertise in pathophysiology and a clear understanding of disease mechanisms, which is crucial for developing targeted interventions in IBD. The research initiatives are structured to generate comprehensive clinical data, thereby informing decision-making processes and enhancing the overall scientific credibility of the company.
Expertise and Scientific Rigor
Palisade Bio Inc presents a model of scientific rigor and precise research methodology in the realm of biopharmaceutical development. Its focus on a clearly defined biological target not only demonstrates strategic foresight but also an adherence to high standards of clinical investigation. This approach fosters a nuanced understanding of gastrointestinal disorders and enables the company to contribute meaningfully to the advancement of innovative therapeutic solutions in the field of healthcare.
Key Attributes
- Clinical-Stage Focus: An active pipeline and ongoing research collaborations underpinning its investigational therapies.
- Niche Expertise: Specialized in targeting the intestinal barrier, critical for addressing inflammatory bowel diseases.
- Robust Research Infrastructure: An emphasis on scientific excellence and methodological precision in developing novel therapeutics.
- Industry Positioning: A distinctive approach that addresses specific unmet medical needs within the biopharmaceutical arena.
Conclusion
By aligning its research efforts with a strategic focus on the intestinal barrier, Palisade Bio Inc has established a clear and informed pathway within the competitive biopharma sector. Its commitment to developing therapies that address core aspects of gastrointestinal health demonstrates both scientific sophistication and a targeted business approach, making it a noteworthy entity among clinical-stage biopharmaceutical companies.
Palisade Bio (NASDAQ: PALI) has initiated dosing in the first Ulcerative Colitis (UC) patient cohort of its ongoing Phase 1a/b study for PALI-2108. The company has completed five single ascending dose (SAD) cohorts and three of four multiple ascending dose (MAD) cohorts, with promising preliminary safety data.
Key highlights include:
- No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs
- Majority of TEAEs were mild, with only one withdrawal at highest MAD dose
- Two MAD cohorts completed within expected therapeutic range showed excellent tolerability
The study aims to evaluate safety, tolerability, and pharmacokinetics in both healthy volunteers and UC patients. The trial will analyze various biomarkers including hsCRP, fecal calprotectin, and colonic tissue histological assessments. Topline data is expected in the first half of 2025.
Palisade Bio (NASDAQ: PALI) announced that two abstracts featuring its lead program PALI-2108 for ulcerative colitis treatment have been selected for presentation at Digestive Disease Week (DDW) 2025, scheduled for May 3-6 in San Diego.
The first presentation, focusing on bioinformatic approaches to PALI-2108 treatment in ulcerative colitis, will explore anti-fibrotic efficacy potential with local PDE4 inhibition in intestinal fibrosis. This session is scheduled for May 4, 2025.
The second abstract, recognized as a Poster of Distinction and rated in the top 10% of all AGA abstracts, will present findings on PALI-2108's colon-specific PDE4 inhibitor prodrug properties. The research demonstrates the drug's bioactivation in the colon, its dose-dependent reduction of colon tissue PDE4B, increased c-AMP, and TNF-α suppression in a mouse colitis model. This presentation is scheduled for May 5, 2025.
Palisade Bio (NASDAQ: PALI) has released a Virtual Investor 'What This Means' segment featuring Dr. Joerg Heyer, Head of Translational Science and Medicine. The segment focuses on the company's recent positive preclinical data for their lead product candidate, PALI-2108, which is being developed for the treatment of Ulcerative Colitis (UC).
The preclinical data was previously presented at the 2025 Crohn's and Colitis Congress. Dr. Heyer discusses the implications of these findings for Palisade's UC development program. The virtual segment is now available for viewing, along with other Virtual Investor events.
Palisade Bio (NASDAQ: PALI) has received CAD$1.39 million from Canada's Scientific Research and Experimental Development (SR&ED) Tax Credit Program through its co-development partner, Giiant Pharma. The funds reimburse pre-clinical development costs for PALI-2108, a treatment for Ulcerative Colitis (UC).
The company is currently conducting a Phase 1a/b single-center, double-blind, placebo-controlled study evaluating PALI-2108's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, along with an open-label study in UC patients. Topline data from this study is expected in the first half of 2025.
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. CEO JD Finley presented the company's top five investment highlights for 2025. The presentation is now available for viewing on the company's website and through the conference platform.
Palisade Bio (NASDAQ: PALI) presented positive preclinical data for PALI-2108, their oral colon-specific PDE4 inhibitor prodrug for ulcerative colitis treatment, at the 2025 Crohn's and Colitis Congress. The drug demonstrated effectiveness in reducing colitis symptoms in mice without CNS toxicity.
Key findings showed that PALI-2108 effectively converts to the active PDE4 inhibitor PALI-0008 in the colon following oral administration in mice, dogs, and humans. The drug outperformed standard treatments in preclinical studies, showing superior potency and target engagement compared to other PDE4 inhibitors.
The company is currently conducting a Phase 1a/b clinical study (NCT06663605) evaluating safety, tolerability, and pharmacokinetics in healthy volunteers and UC patients. Topline data is expected in the first half of 2025.
Palisade Bio (NASDAQ: PALI) announced the acceptance of its abstract for poster presentation at the 2025 Crohn's & Colitis Congress in San Francisco. The presentation, scheduled for February 7, 2025, will showcase research on PALI-2108, a colon-specific PDE4B inhibitor prodrug. The poster, titled 'PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model,' will be presented during the Poster and Exhibition Hall Reception at Moscone West.
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company specializing in autoimmune, inflammatory, and fibrotic diseases, has announced its upcoming participation in the LIVE! with Webull Corporate Connect: Healthcare Investment Webinar. JD Finley, the company's Chief Executive Officer, will present at the virtual event scheduled for Wednesday, January 29, 2025, at 2:20 PM ET.
The presentation will be part of the Virtual Biotech Investment Webinar segment of the conference, offering investors an opportunity to gain insights into Palisade Bio's developments and strategic direction in the healthcare sector.
Palisade Bio (NASDAQ: PALI) has successfully completed all five Single Ascending Dose (SAD) cohorts and advanced to Multiple Ascending Dose (MAD) cohorts in its Phase 1a/b study of PALI-2108 for Ulcerative Colitis treatment. The SAD study, testing doses from 15mg to 450mg, demonstrated favorable safety and tolerability with no serious adverse events or treatment-related laboratory abnormalities.
The preliminary pharmacokinetic analysis showed PALI-2108's delayed-release and extended-release characteristics, providing sustained, dose-dependent drug exposure with high local concentrations in the colon. Only mild treatment-emergent adverse events were observed at the highest dose of 450mg.
The ongoing MAD portion will assess repeat dosing and further evaluate safety and pharmacokinetics in both healthy volunteers and UC patients. The company remains on track to report topline data in the first half of 2025.
Palisade Bio (NASDAQ: PALI), a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company has issued stock options to a new employee as part of its 2021 Inducement Plan.
The grant consists of options to purchase 2,600 shares of common stock, issued on January 3, 2025, with an exercise price matching the closing price on the grant date. The options will vest quarterly over a three-year period, subject to continued employment with the company.
FAQ
What is the current stock price of Palisade Bio (PALI)?
What is the market cap of Palisade Bio (PALI)?
What is the core focus of Palisade Bio Inc?
Which medical conditions does the company target?
How does Palisade Bio Inc generate revenue?
What sets the company apart from its competitors?
What stage of development is Palisade Bio Inc currently in?
How does the company contribute to advancements in healthcare?
What are the main components of its research pipeline?
